الفهرس 
PharmacokineticsOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Clopidogrel is an antiplatelet and antithrombotic prodrug that inhibits adenosine diphosphate - mediated platelet activation and aggregation by selectively and irreversibly blocking platelet purinergic P2Y12 receptors. Clopidogrel used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebro vascular disease. It has poor oral bioavailability due to protonation in the stomach which limits its absorption from the upper part of the GIT, Once in the intestine the drug will undergo slow dissolution which can provide the rate limiting step for drug absorption. Even after absorption the drug will face the Pg-P efflux transporters which reduce further the amount of drug absorbed and possible premature degradation in the intestine as the drug is liable to carboxylic esterase 1, carboxylic esterase 2 and butyrylcholine esterase which hydrolyze the ester liberating the free acid component of the drug.